Chronic kidney disease can progress for years without obvious symptoms, making routine screening during annual checkups ...
Maze Therapeutics Inc. MAZE shares are down on Wednesday following the announcement of topline data from the Phase 2 HORIZON ...
Good morning, and welcome to Sarepta's preliminary data readout of its Phase I/II studies for DM1 and FSHD. As a reminder, today's program is being recorded. At this time, I'll turn the call over to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results